NVX-207 | 745020-66-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: NVX-207
• 英文别名: 2-amino-3-hydroxy-2-(hydroxymethyl)propyl (3-O-acetyl)betulinate；acetylbetulinic acid 2-amino-3-hydroxy-2-hydroxymethyl-propyl ester；Q2RA5BK4A7；[2-amino-3-hydroxy-2-(hydroxymethyl)propyl] (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate
• CAS: 745020-66-0
• 化学式: C₃₆H₅₉NO₆
• 分子量: 601.868
• InChiKey: KQZVSTAVTJCKDG-DRSBITMPSA-N

物化性质

• 沸点：
  664.8±55.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：125 mg/mL（207.69 mM）

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  43
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  7

安全信息

• 储存条件：
  2-8℃

制备方法与用途

NVX-207是一种桦木酸衍生物，并且具有抗癌活性。

反应信息

• 作为反应物：
  描述：

  NVX-207 在 甲醇 、 sodium methylate 作用下， 以 甲醇 为溶剂， 以90%的产率得到2-amino-3-hydroxy-2-(hydroxymethyl)propyl betulinate
  参考文献：
  名称：

  五环环戊烷型三萜衍生物的小结构变化导致它们的抗癌特性发生显着差异

  摘要：

  在目前的研究中，合成了五种新的甜菜碱和甜菜酸衍生物，并研究和讨论了这种结构变化对抗癌活性的影响。研究了桦木和桦木酸衍生物的抗增殖活性对不同组织起源的八种肿瘤细胞系的抑制作用。所述衍生物在微摩尔浓度下对靶肿瘤细胞系发挥剂量依赖性的抗增殖作用。细胞死亡对结肠癌细胞系HT-29细胞凋亡模式诱导最活跃的化合物5，2-氨基-3-羟基-2-（羟甲基）丙基（3- ø -乙酰基）桦木，和9，2 -氨基-3-羟基-2-（羟甲基）丙基丁烯酸酯。用5处理HT-29细胞9和9诱导了凋亡，这是通过染料排斥试验（锥虫蓝）以及在DNA片段测定和FITC膜联蛋白V测定中典型梯形的出现而观察到的。还介绍了由化合物5引起的细胞周期扰动。

  DOI：

  10.1016/j.ejmech.2010.04.018
• 作为产物：
  描述：

  白桦脂酸 在 吡啶 、 4-二甲氨基吡啶 、 草酰氯 作用下， 以 1,4-二氧六环 、 苯 为溶剂， 反应 58.0h， 生成 NVX-207
  参考文献：
  名称：

  COMPOSITIONS AND METHODS FOR TREATMENT OF INFECTION AND NOVEL COSMECEUTICAL PREPARATIONS

  摘要：

  Disclosed are methods of treating or preventing infection in a mammal in need thereof, by administering the following compound, or related compounds, to a mammal, as well as cosmeceutical preparations and methods of using the same to influence the appearance and/or biological function of the skin by topical application of the preparations comprising the following compound, or related compounds:

  公开号：

  US20220296610A1

文献信息

• [DE] MEDIKAMENT ZUR WACHSTUMSINHIBIERUNG VON TUMOREN<br/>[EN] MEDICAMENT FOR INHIBITING TUMOUR GROWTH<br/>[FR] MEDICAMENT POUR INHIBER LA CROISSANCE DE TUMEURS
  申请人：SELZER EDGAR

  公开号：WO2004072092A1

  公开（公告）日：2004-08-26

  Die vorliegende Erfindung betrifft neue Derivate der Betulinsäure mit verstärkter Wirksamkeit zur Behandlung von Karzinomen und HIV-Erkrankung, ein Verfahren zur Herstellung derartiger neuer Derivate der Betulinsäure sowie ihre Verwendung als Pharmazeutika.

  这项发明涉及新的具有增强效果的苹皮酸衍生物，用于治疗癌症和艾滋病，一种制备这种新苹皮酸衍生物的方法以及它们作为药物的用途。
• COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION AND HYPERKERATOTIC LESIONS
  申请人：Jansen Burkhard

  公开号：US20110077297A1

  公开（公告）日：2011-03-31

  A method of treating inflammation and hyperkeratotic lesions in a mammal in need thereof, by administering the following compound (NVX-207), a related compound, or a pharmaceutically acceptable salt thereof to the mammal.

  一种治疗哺乳动物炎症和角化病变的方法，通过向哺乳动物投与以下化合物（NVX-207），相关化合物或其药学上可接受的盐。
• In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and invivo safety assessment of the compound NVX-207 in two horses
  作者：G. Liebscher、K. Vanchangiri、Th. Mueller、K. Feige、J.-M.V. Cavalleri、R. Paschke

  DOI：10.1016/j.cbi.2016.01.002

  日期：2016.2

  Betulinic acid, a pentacyclic triterpene, and its derivatives are promising compounds for cancer treatment in humans. Melanoma is not only a problem for humans but also for grey horses as they have a high potential of developing melanoma lesions coupled to the mutation causing their phenotype. Current chemotherapeutic treatment carries the risk of adverse health effects for the horse owner or the treating veterinarian by exposure to antineoplastic compounds. Most treatments have low prospects for systemic tumor regression. Thus, a new therapy is needed. In this in vitro study, Betulinic acid and its two derivatives B10 and NVX-207, both with an improved water solubility compared to Betulinic acid, were tested on two equine melanoma cell lines (MelDuWi and MellJess/HoMelZh) and human melanoma (A375) cell line. We could demonstrate that all three compounds especially NVX-207 show high cytotoxicity on both equine melanoma cell lines. The treatment with these compounds lead to externalization of phosphatidylserines on the cell membrane (AnnexinV-staining), DNA-fragmentation (cell cycle analysis) and activation of initiator and effector caspases (Caspase assays). Our results indicate that the apoptosis is induced in the equine melanoma cells by all three compounds. Furthermore, we succeed in encapsulating the most active compound NVX-207 in 2-Hydroxyprolyl-beta-cyclodextrine without a loss of its activity. This formulation can be used as a promising antitumor agent for treating grey horse melanoma. In a first tolerability evaluation in vivo the formulation was administered every one week for 19 consecutive weeks and well tolerated in two adult melanoma affected horses. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
• METHODS AND COMPOSITIONS FOR INHIBITING TUMOR GROWTH
  申请人：Selzer Edgar

  公开号：US20080214516A1

  公开（公告）日：2008-09-04

  The present invention relates to novel betulinic acid derivatives with increased activity for the treatment of carcinomas and HIV diseases, a method for preparing such novel betulinic acid derivatives as well as their use as pharmaceuticals.
• US7312205B2
  申请人：——

  公开号：US7312205B2

  公开（公告）日：2007-12-25